March 1, 2026. Dr. Gyawali is the first author and a co-chair for the newly published ASCO Guidelines on the use of white blood cell (WBC) colony stimulating factors in patients with cancer receiving systemic treatment. These guidelines were published in the Journal of Clinical Oncology.
These updated guidelines help shared decision making among patients, because it quantifies benefits, harms, and the quality of evidence. Importantly, this guideline not only discusses when to use WBC growth factors, but also when not to use and what alternatives are available, along with cost, convenience, and considerations for patient factors. Read the new guideline here.
Dr. Gyawali also spoke on the ASCO Guidelines Podcast discussing this guideline update with Dr. Tessa Cigler. In a separate interview with ASCO Daily News, Dr. Gyawali also highlights what’s new and novel with these guidelines, and why oncologists should read these guidelines in full even if they have read the previous version, which was published a decade ago.
Dr. Bishal Gyawali 
Leave a comment